RBC Capital Maintains Outperform on Evommune, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 95.3%

Neg 95.3% Neu 0% Pos 0%

RBC Capital analyst Brian Abrahams maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $29 to $21.